Log says FMR LLC now controls 5% ordinary shares
TL;DR
FMR LLC and Abigail P. Johnson disclosed a 10% stake in AGOMAB Therapeutics via SEC filing, with FMR holding voting power and Johnson having dispositive power. This passive investment triggers reporting requirements as it exceeds 5% ownership.
Tags
FMR LLC and Abigail P. Johnson have disclosed a 10% beneficial ownership stake in AGOMAB Therapeutics SA (AGMB) through a Schedule 13G filing with the U.S. Securities and Exchange Commission, dated March 5, 2026. The filing indicates FMR LLC holds 4,873,680 ordinary shares, representing sole voting and dispositive power over the position. Abigail P. Johnson, a related individual, is reported to have sole dispositive power over the same share count but no voting authority. The ownership threshold exceeds 5%, triggering the institutional investment manager's obligation to file under SEC rules.
The Schedule 13G specifies the shares are held in the ordinary course of business, with no intent to influence control of the issuer. While the filing notes potential third-party rights to dividends or sale proceeds, no other entity is identified as holding more than 5% of AGMB's outstanding shares. Transactional details, such as acquisition dates or price ranges, are not included in the disclosure.
This update reflects passive investment activity by FMR LLC, a registered investment company, and aligns with standard reporting requirements for institutional shareholders. Investors should refer to the complete Schedule 13G for additional context, including exhibit references and legal certifications.
